Internal Medicine

Data show the lifetime risk of late AMD ranged from 4.4% for carriers of the nonrisk genotype to 9.4% and 26.8% for heterozygous and homozygous carriers.

An analysis of PSOARING 1 and 2 data show the topical therapy is efficacious across a wide spectrum of psoriatic disease and patient demographics.

Tenofovir was linked to a decreased incidence rate of HCC compared to entecavir. However, this difference was not considered statistically significant.

The majority of patients in the phase 2 study met the primary efficacy endpoint of a greater than or equal to a 10% reduction in total stool output over the 6-week efficacy evaluation period.

Investigators did not observe a benefit with the anti-VEGF in preventing intermediate AMD eyes from converting to neovascular disease versus sham.

Dr. Rindos emphasizes the importance of referring patients to an OBGYN if they're experiencing heavy bleeding or painful cramping.

New data suggest a combination of cosmetic and psychiatric care for patients with the chronic pigmentation condition may provide multi-systemic benefit.

The issued marketing denial orders require the country's most popular vaping device company remove all commercial products on the basis of insufficient toxicity data.

At 12 months, the mean VA change from baseline was 17.6 for BRVO patients and 18.6 for CRVO patients in the Netherlands.

Results from a cross-sectional survey suggest consistent patient preferences for treatment outcomes and means of administration.

The survey identified long-term health complications of sickle cell disease as a primary concern among patients and providers and overall understanding of the disease needs more educational support.

With World Sickle Cell Day approaching, Dr. Titi Fasipe reflects on the developments within the field, such as the continued conversation of disparities and the increased comfort level with new therapies.

In the Archway trial, 93.2% of patients preferred treatment with ranibizumab delivered via the PDS compared to only 1.3% of patients who preferred intravitreal injections.

National prescribing cohort data suggest clinicians buck against the recommended use of the antidepressant.

Combination treatment was equal to anti-VEGF monotherapy in functional and structural outcomes in the treatment of macular edema due to BRVO.

Vutrisiran is the first and only FDA-approved treatment that’s demonstrated reversal in neuropathy impairment with subcutaneous administration once every 3 months.

New data suggest race and ethnicity, income, education, rural vs urban residence, and living in a food desert all were independently associated with poor diet quality.

The decision comes after the company announced positive phase 3 data for the combination vaccine candidate in adults aged 60 years and older.

The study popuation had a higher visual acuity at 12 months, despite receiving fewer aflibercept injections.

Some of the favorable responses to voxelotor treatment and signs of hematologic response after voxelotor treatment included increased Hb levels, decreased reticulocyte percentage, and decreased total bilirubin.

The phase 3 research being presented at the EULAR 2022 conference evaluated the efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis.

The investigators found pharmacotherapy for AUD was associated with a lower incidence of hepatic decompensation in patients with cirrhosis.

Efanescotocog alfa is the first factor VIII therapy to be granted Breakthrough Therapy designation by the FDA.

Bristol Myers Squibb shares positive phase 2 results evaluating deucravacitinib in patients with moderate-to-severe systemic lupus erythematosus.

Fidaxomicin had a 13.5% higher rate of 4-week sustained response compared to vancomycin and 13.2% higher rate for 8-week sustained response.

Patients with ≥1 CDI-related admissions versus no CDI admissions experienced higher rates of 6-month readmission and annual cost across all hospitalizations.

SER-109 engraftment was durable through week 24 and significantly higher than placebo at all time points for all comparisons.

New data suggests there is no connection between ustekinumab and the risk of malignancies.

There are several companies preparing new treatments for recurrent C difficile infections.

There are several potential treatments on the horizon for C difficile infections.